Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHRM.L Regulatory News (PHRM)

  • There is currently no data for PHRM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Loan Agreement & Convertible Loan Note Extension

28 Jul 2015 07:00

RNS Number : 2316U
Phorm Corporation Limited
28 July 2015
 

28 July 2015

 

Phorm Corporation Limited

("Phorm" or the "Company")

 

Loan Agreement and Extension of Convertible Loan Notes

Phorm (AIM: PHRM), a leading internet personalisation technology company, announces that it has entered into unsecured loan agreements with each of Michael Bigger and Arminius Verwaltung AG, an existing shareholder and a private lender respectively (the "Lenders"), and that the final redemption date of its pre-existing convertible secured loan notes (the "Loan Notes") issued to Viollette Company Limited ("Viollette") and Meditor European Master Fund Limited ("Meditor") in April 2013, has now been formally extended.

Loan Agreements

The Lenders have agreed to provide Phorm with an unsecured term loan of, in aggregate, £350,000 principal amount (the "Loan"). In accordance with the terms of the loan agreements, Phorm shall pay interest on the Loan at a rate of 5 per cent. per annum. The Loan, together with accrued interest thereon, is repayable 6 months from the date of execution of the loan agreements although such repayment date can be extended for a further 6 month period by mutual agreement between the parties. Upon repayment, Phorm is obliged to pay the Lenders an additional 15 per cent. of the Loan principal amount as a redemption fee (the "Redemption Fee").

In addition, Phorm has granted the Lenders an option such that they can elect that repayment of the principal amount of the Loan, together with accrued interest thereon and the Redemption Fee, be satisfied, in full, by way of the issue of new ordinary shares in the capital of Phorm at the same price per share as the Company's next equity fundraising.

The Company intends to use the net proceeds from the Loan for general working capital purposes and intends to raise additional equity and/or debt finance in the near term to fund its ongoing working capital requirements. A further announcement will be made in due course.

Extension of Convertible Loan Notes

Save in the event that the outstanding Loan Notes are otherwise converted, the outstanding principal amount of, in aggregate, £1.95 million, together with accrued interest thereon, will now be repayable on 22 April 2017. Save for the extension of the final redemption date, all other key terms of the Loan Notes announced on 23 April 2013 remain unaltered. As at 30 June 2015, the total liability for the Company (inclusive of accrued interest) in respect of the Loan Notes was approximately £2.38 million.

 

Related party transactions

Viollette and Meditor each hold £975,000 principal amount of the Loan Notes and are interested in approximately 25.0 per cent. and 26.3 per cent. respectively of the Company's issued ordinary share capital.

By virtue of Viollette and Meditor currently being substantial shareholders in the Company, the abovementioned formal extensions of their Loan Notes are considered to be related party transactions for the purposes of Rule 13 of the AIM Rules for Companies. Accordingly, the directors of Phorm consider, having consulted with Strand Hanson Limited (the Company's Nominated Adviser), that the formal extensions of both Viollette's and Meditor's Loan Notes are fair and reasonable insofar as the Company's shareholders are concerned.

-Ends-

For further information please contact:

Phorm Corporation Limited

Timothy Smith (analysts and investors) +44 20 3397 6001

UK Investors

Mirabaud Securities LLP (Broker) +44 20 7321 2508

Jason Woollard

Peter Krens

Strand Hanson Limited (Nominated Adviser) +44 20 7409 3494

James Harris

Matthew Chandler

James Dance

US Investors

Lippert/Heilshorn and Associates (Investor Relations) +1 212 838 3777

John Heilshorn

 

About Phorm

 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

 

Phorm's industry leading technology enables its Internet Service Provider ("ISP") partners to offer a new type of online advertising platform and a free consumer internet content feature, ensuring more relevant advertisements and personalised content for opted-in users.

 

Phorm's advertising platform revolutionises current standards of online privacy, fully protecting the identity of consumers. Phorm's solution is completely opt-in. Only those users consenting to the service are profiled and only ever on an anonymous basis.

 

Phorm's partners include leading ISPs, Publishers, Advertising Networks and Advertisers.

 

Phorm, under a predecessor holding company, was admitted to trading on the AIM market of the London Stock Exchange in 2004.

 

For more information, please visit: www.phorm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBDLLLEDFBBBE
Date   Source Headline
14th Apr 201610:00 amRNSUpdate and Resignation of Nominated Adviser
16th Mar 201612:37 pmRNSIssue of US$500,000 of Convertible Loan Notes
16th Mar 20167:00 amRNSIssue of US$500,000 of Convertible Loan Notes
25th Feb 20168:02 amRNSFunding Update and Statement re Suspension
25th Feb 20167:55 amRNSSuspension - Phorm Corporation Limited
4th Feb 20166:05 pmRNSFunding Update
1st Feb 20163:49 pmRNSSubscription Update, New Subscription & Loan
21st Jan 20167:00 amRNSPhorm Awarded TRUSTe Certified Privacy Seal
18th Jan 20167:00 amRNSSubscription & Operational Update
5th Jan 20162:00 pmRNSTR-1: Notification of major interest in shares
23rd Dec 20151:00 pmRNSRevised Non-Executive Director Compensation
22nd Dec 20157:00 amRNSDirectorate Change
7th Dec 20157:00 amRNSRepricing of Options
3rd Dec 201511:00 amRNSPhorm Enables Hover Rate with Insomnis Media
1st Dec 20157:00 amRNSNew Share Option Plan and Grant of Options
18th Nov 20157:00 amRNSTR-1: Notifications of Major Interests in Shares
28th Oct 20157:00 amRNSPartnering Agreement with INSOMNIS Media Limited
20th Oct 20157:00 amRNSAgreement with Causemo, Inc.
13th Oct 20157:00 amRNSPhorm Hires Chief Revenue Officer
9th Oct 20157:00 amRNSAgreement with Boston Globe Media Group
30th Sep 20151:33 pmRNSInterim Results
28th Aug 20152:38 pmRNSResult of AGM
10th Aug 20157:00 amRNSNotice of Annual General Meeting
7th Aug 20157:48 amRNSEquity fundraising of approximately £3.2 million
29th Jul 20157:02 amRNSUpdate re Board Changes
28th Jul 20157:00 amRNSLoan Agreement & Convertible Loan Note Extension
15th Jul 201511:21 amRNSBoard and Management Changes
3rd Jul 20157:00 amRNSOperational Update
2nd Jul 20157:16 amRNSDirectorate Change
30th Jun 20157:00 amRNSAnnual Financial Report
8th May 20154:00 pmRNSTR-1: Notification of major interest in shares
22nd Apr 20157:00 amRNSEquity Fundraising of £6.0 million Gross
21st Apr 20154:22 pmRNSOperational Update
16th Mar 20153:45 pmRNSDirectorate Change
25th Feb 20157:02 amRNSBoard Changes
19th Jan 20157:00 amRNSEquity fundraising of approximately £6.25 million
16th Jan 20157:21 amRNSOperational Update
8th Dec 20147:00 amRNSEquity Fundraising
28th Oct 20147:00 amRNSTR-1: Notification of major interest in shares
8th Oct 20147:00 amRNSEquity fundraising of £4.47 million
6th Oct 20147:00 amRNSOperational Update
22nd Aug 20147:05 amRNSSubscription To Raise £2.4 million
22nd Aug 20147:00 amRNSInterim Results
24th Jul 20142:31 pmRNSResult of Annual General Meeting
27th Jun 20147:30 amRNSGlobal Operations Update
27th Jun 20147:05 amRNSNotice of Annual General Meeting and Board Changes
27th Jun 20147:00 amRNSFinal Results for the Year Ended 31 December 2013
23rd Apr 20144:25 pmRNSTR-1: Notification of major interest in shares
14th Apr 201412:40 pmRNSResult of EGM
27th Mar 20147:00 amRNSProposed £10m Placing & Notice of EGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.